GLP-1 Check — India's GLP-1 Information & Self-Assessment Tool
All Semaglutide Brands India
Generic SemaglutideType 2 Diabetes + Obesity
Lupin (via Zydus) logo

Semanext/ LivariseGeneric semaglutide for type 2 diabetes + obesity in India 2026

by Lupin (via Zydus) · ₹2,200/month · DCGI approved March 2026

Active ingredient
Semaglutide (GLP-1 receptor agonist)
Indication
Type 2 Diabetes + Obesity
Manufacturer
Lupin Limited
DCGI status
Approved March 2026
Price (MRP)
₹2,200/month
Format
Reusable pen
Same Zydus reusable-pen platform as Semaglyn
Prescription
Schedule H — required

How Semanext compares

Semanext is Lupin's brand of generic semaglutide, manufactured under licence from Zydus on the same reusable-pen platform as Semaglyn. Lupin's strength is its commercial reach into endocrinology and pulmonology prescribers, particularly in Western and Northern India. Livarise is Lupin's sister brand for parallel channel coverage.

About Lupin (via Zydus)

Lupin is India's third-largest pharma exporter and has historically focused on respiratory and CNS franchises. Its semaglutide entry via the Zydus platform avoids the manufacturing-scale-up timeline its competitors face, accelerating time-to-market.

Who is Semanext for?

Semanext is approved in India for both type 2 diabetes and chronic weight management in adults with obesity. Indian guideline eligibility typically requires BMI ≥27.5 (obesity indication) or HbA1c above target on first-line therapy (T2D indication). Patients with BMI ≥25 + comorbidities (PCOS, NAFLD, hypertension, sleep apnea) may also qualify under specialist judgment.

Not sure if you qualify? Take the 5-minute Indian-guideline eligibility check →

Semanext for specific conditions

Semanext for PCOS →Semanext for fatty liver (NAFLD/MASLD) →Semanext for hypertension + obesity →Semanext for sleep apnea + obesity →

Semanext cost in India

MRP for Semanext: ₹2,200/month. Actual pharmacy pricing varies by city, pharmacy, and channel. Online prescription pharmacies typically offer modest discounts off MRP with cold-chain delivery; hospital pharmacy pricing is usually at MRP.

Compare with all India brands: GLP-1 therapy cost in India 2026 →

Compared to other GLP-1 brands in India

Semanext is an Indian generic semaglutide. Same active molecule as Ozempic and Wegovy (Novo Nordisk innovator brands), with clinical efficacy that follows the molecule rather than the brand. Other Indian generics include Sundae, Noveltreat, Obeda, Semaglyn, Sembolic, and Samakind — all at similar price points.

All GLP-1 comparisons →All Indian semaglutide brands →Clinical evidence library →GLP-1 blog (India) →

Semanext — frequently asked questions

Is Semanext available in India? Is it DCGI-approved?+
Yes — Semanext is DCGI-approved and currently available across India. The drug received DCGI approval in March 2026 for both type 2 diabetes and obesity, manufactured by Lupin Limited. It is distributed through licensed retail and online prescription pharmacies and hospital pharmacies across Indian metros and most tier-2 cities. Semanext is a Schedule H drug — a doctor's prescription is required. Take the GLP-1 Check 5-minute Indian-guideline assessment to see if you qualify.
What does Semanext cost in India in 2026?+
Semanext is priced at ₹2,200/month. Actual pharmacy pricing may vary by city and channel. For brand-by-brand price comparisons across all India brands, see our cost guide. Take the GLP-1 Check 5-minute Indian-guideline assessment to see if you qualify.
Do I need a prescription to buy Semanext?+
Yes — Semanext is a Schedule H drug in India and can only be dispensed against a valid prescription from a registered medical practitioner. Any legitimate online prescription pharmacy will require you to upload your prescription before order fulfillment.
Who is Semanext for?+
Semanext is approved for both type 2 diabetes and obesity in India. Indian guideline eligibility typically requires BMI ≥27.5 (obesity indication) or HbA1c above target on first-line therapy (T2D indication), often with comorbidities at BMI ≥25. Take the GLP-1 Check 5-minute Indian-guideline assessment to see if you qualify.
How does Semanext compare to Ozempic and Wegovy?+
Semanext contains the same active molecule (semaglutide) as Ozempic and Wegovy. Clinical efficacy is comparable; the difference is brand, manufacturer support, pen design, and price. Semanext (₹2,200/month) is meaningfully cheaper than Ozempic (₹5,660+/month) or Wegovy (up to ₹16,400/month) — useful for cost-sensitive patients on long-term therapy.
Where can I buy Semanext in India?+
Semanext is a Schedule H drug — available through licensed retail and online prescription pharmacies and hospital pharmacies across India with a doctor's prescription. Always buy from a licensed pharmacy to avoid counterfeit products; never use sources that dispense without verifying a prescription. Take the GLP-1 Check 5-minute Indian-guideline assessment to see if you qualify.
Official

Manufacturer announcement

Lupin — Zydus licensing agreement for semaglutide (March 2026)

Additional source

Pearce IP — generic semaglutide India launches

GLP-1 Check is informational, not a medical diagnosis. Semaglutide is a Schedule H drug in India and requires a prescription from a registered medical practitioner. Always consult a qualified physician before starting any treatment.

Are you eligible for Semanext?

Take the free 5-minute triage to check your GLP-1 readiness against Indian clinical guidelines.

Check My Eligibility →

Looking at other brands?

See full price comparison across all 25+ DCGI-approved brands →